1 not yet recruiting, 1 recruiting, 1 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow CTX-471: new trials by email Literature Review of CTX-471 trials Research Report on CTX-471
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms CTX-471 - Neuroendocrine Neoplasm, Neuroendocrine Carcinomas | Phase 2 | Not yet recruiting | Compass Therapeutics | 58 | 2026-09-01 | 2026-07-06 |
| Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma CTX-009, CTX-471 - Glioblastoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 54 | 2026-06-16 | 2026-06-22 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies CTX-471, Pembrolizumab (KEYTRUDA®) - Locally Advanced Solid Tumor, Metastatic Cancer | Phase 1 | Terminated | Compass Therapeutics | 100 | 2019-05-17 | 2026-10-09 |
Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Neuroendocrine Tumors (1) · Small Cell Lung Carcinoma (1)
Compass Therapeutics (2) · Washington University School of Medicine (1)
United States (2)
Tanner M Johanns, MD, PhD (1) · Thomas Scheutz, MD, PhD (1)